Last reviewed · How we verify
AN2728 ointment, 2%
AN2728 ointment, 2% is a Topical corticosteroid Small molecule drug developed by Pfizer. It is currently in Phase 2 development for Eczema, Psoriasis.
AN2728 ointment, 2% is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system's response.
AN2728 ointment, 2% is a topical corticosteroid that reduces inflammation and itching by suppressing the immune system's response. Used for Eczema, Psoriasis.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Big-pharma sponsor
+3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AN2728 ointment, 2% |
|---|---|
| Sponsor | Pfizer |
| Drug class | Topical corticosteroid |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the production of pro-inflammatory cytokines and enzymes, thereby reducing the symptoms of skin conditions such as eczema and psoriasis. The exact mechanism of action is not fully understood, but it is thought to involve the suppression of the immune system's response to allergens and irritants.
Approved indications
- Eczema
- Psoriasis
Common side effects
- Skin atrophy
- Hypersensitivity reactions
Key clinical trials
- Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%) Versus Tacrolimus Ointment (0.1%) for the Topical Treatment of Atopic Dermatitis (PHASE4)
- Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis (PHASE4)
- Crisaborole 2% Versus Tacrolimus 0.1% in Children With Mild to Moderate Atopic Dermatitis (PHASE3)
- Microneedling Combined With Topical Crisaborole 2 % Ointment in Treatment of Vitiligo. (NA)
- Skin bioMARkers for Atopic Eczema Therapy Evaluation (PHASE2)
- Eucrisa for Atopic Dermatitis (PHASE1)
- Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis (PHASE4)
- Topical Crisaborole in Patients with Alopecia Areata (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AN2728 ointment, 2% CI brief — competitive landscape report
- AN2728 ointment, 2% updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about AN2728 ointment, 2%
What is AN2728 ointment, 2%?
How does AN2728 ointment, 2% work?
What is AN2728 ointment, 2% used for?
Who makes AN2728 ointment, 2%?
What drug class is AN2728 ointment, 2% in?
What development phase is AN2728 ointment, 2% in?
What are the side effects of AN2728 ointment, 2%?
Related
- Drug class: All Topical corticosteroid drugs
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Eczema
- Indication: Drugs for Psoriasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing